Speaker Profile
Program, Alliance, and Business Development Manager, Oxford Biotherapeutics
Biography
Matthew joined Oxford Biotherapeutics in 2022 as a program manager. He is dedicated primarily to external innovation, coordinating and delivering target validation data for partnership programs, and business development, developing content and strategies for future partnerships. He currently oversees the ADC development pipeline of the 10 partnered programs in collaboration with Immunogen. He has a Master of Science from UC Berkeley and brings years of experience in early-stage biotech startups. He is passionate about maximizing the quantity and quality of science produced every day.
Talk
OGAP-Verify: An Enhanced Oncology Target Discovery Platform
OBT is a clinical stage oncology company with a pipeline of first-in-class antibody-based therapies. OBT utilizes OGAP-Verify its proprietary proteomic target discovery platform for ADC, CAR-T and bispecific novel target discovery.
Emerging Therapeutics Showcase:
Oxford Biotherapeutics
OBT is a clinical stage oncology company with a pipeline of first-in-class antibody-based therapies. OBT utilizes OGAP-Verify its proprietary proteomic target discovery platform for ADC, CAR-T and bispecific novel target discovery.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
